First-of-Its-Kind Pediatric Research and Funding Collaboration to Speed Development of Medications for Autoimmune Diseases

Seattle Children’s Research Institute and Kineta Launch the Alliance for Children’s Therapeutics

Seattle Children’s Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children’s Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.

“Funding for pediatric research lags disproportionately behind research funding for adult diseases. Thirty percent of the U.S. population is under the age of 21, and yet only six percent of the entire National Institutes of Health’s budget is devoted to pediatric medicine and care,” said Jim Hendricks, PhD, president of Seattle Children’s Research Institute. “This gap results in limited development of new therapies for children, who now often have no other choice than to use adult-only tested medications.”

There are significant barriers in developing pediatric therapies and the lack of pediatric medication use information poses risks to children and teens. The shortage of appropriate formulations may deny access and expose them to medications that were not designed for their growing bodies. The challenge of recruiting sufficient numbers of pediatric patients for clinical research also delays the development of better therapies for pediatric diseases and conditions.

In 2013, the U.S. Food and Drug Administration (FDA) approved 27 new drugs; just seven new drugs were approved for pediatric use that same year. And of the 55,000 clinical trials conducted between 2005 and 2010, only nine percent were designed for children.

Translating Research into Better Medical Treatments for Children and Teens

Bringing together one of the U.S.’s top five pediatric research institutions with a leading biotechnology company, ACT aims to speed development of medicines for children and teens with autoimmune diseases.

Funding is needed to propel this pediatric research forward. ACT will rely on a unique and collaborative funding model that combines philanthropic gifts made to Seattle Children’s Research Institute with equity investments made to Kineta.

“For too long pediatric studies have been the neglected component of clinical trials,” said Charles Magness, PhD, Kineta president and chief executive officer. “Kineta has a drug candidate that has completed two adult clinical trials and is well positioned for a clinical trial which could make a real advancement for autoimmune diseases in children.”

For their first collaborative project, researchers from Kineta and Seattle Children’s Research Institute have already begun conducting pre-clinical laboratory tests to advance Kineta’s lead compound, called ShK-186, as a potential treatment for lupus nephritis, an autoimmune disease that causes kidney inflammation. While medications available today for lupus nephritis reduce the disease’s resulting inflammation, they also suppress the immune system, a side effect that is particularly concerning in children. Early pre-clinical research studies have indicated that ShK-186, which is derived from sea anemone venom, reduces inflammation while leaving the immune system intact.

“There is a huge need for medications designed for children and teens,” said 18-year-old Seattle Children’s Hospital patient Kathia Vega Flores, who was diagnosed with lupus when she was 11. “A diagnosis of lupus can present daily challenges not only for the person with the disease, but the whole family. I am so encouraged to see ongoing research and possible new treatments for lupus and other autoimmune diseases that will help so many children in need of better medications and care options.”

In addition to the previously mentioned autoimmune diseases, which afflict close to a million children and teens in the U.S., ShK-186 has shown early indications of being a potential therapy for allergic asthma. It is estimated that nearly 10 million children in the U.S. are impacted by asthma.

Initial funding will help move ACT’s lupus nephritis research into a clinical setting. It will also support work to adapt ShK-186 to become a viable treatment for other autoimmune diseases.

Additional Information

Contact for Media

About Kineta, Inc.

Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of novel drug candidates derived from leading edge scientific research. Our world-class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website,

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children’s bold initiative – It Starts With Yes: The Campaign for Seattle Children’s – to transform children’s health for generations to come.

For more information, visit or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.